Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer

Japanese Journal of Clinical Oncology

Volumn 26, Issue 3, 1996, Pages 157-163

  Akimoto, Susumu ^a   Akakura, Koichiro ^a   Shimazaki, Jun ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Bone metastasis; Carboxyterminal propeptide of type I procollagen; Prostate cancer; Pyridinoline cross linked carboxyterminal telopeptide of type I collagen

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I CARBOXY TERMINAL PEPTIDE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGED; ARTICLE; BLOOD; BONE TUMOR; HUMAN; MALE; METASTASIS; PATHOLOGY; PROSTATE HYPERTROPHY; PROSTATE TUMOR; ROC CURVE;

AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BONE NEOPLASMS; COLLAGEN; COLLAGEN TYPE I; HUMANS; MALE; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 0030163149     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.jjco.a023200     Document Type: Article

References (26)

1. Jacobs SC: Spread of prostatic cancer to bone. Urology 21: 337-344, 1983
2. Smith PH, Bono A, Calais da Silva F, Debruyne F, Denis L, Robinson P, Sylvester R, Armitage TG: Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer: a subanalysis of EORTC trial 30853. The EORTC Urological Group. Cancer 66: 1009-1016, 1990
3. Pollen JJ, Witztum KF, Ashburn WL: The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. Am J Roenigenol 142: 773-776, 1984
4. Mundy AR: Urinary hydroxyproline excretion in carcinoma of the prostate: a comparison of 4 different modes of assessment and its role as a marker. Br J Urol 51: 570-574, 1979
5. Body JJ, Delmas PD: Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol Metab 74: 471-475, 1992
6. Miyamoto KK, McSherry SA, Robins SP, Besterman JM, Mohler JL: Collagen cross-linked metabolites in urine as markers of bone metastases in prostatic carcinoma. J Urol 151: 909-913, 1994
7. Price PA, Parthemore JG, Deftos LJ: New biological marker for bone metabolism: measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects ad patients with bone disease. J Clin Invest 66: 878-883, 1980
8. Cooper EH, Whelan P, Purves D: Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer. Prostate 25: 236-242, 1994
9. Melkko J, Niemi S, Risteli L, Risteli J: Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 36: 1328-1332, 1990
10. Francini G, Gonnelli S, Petrioli R, Bruni S, Marsili S, Aquino A, Camporeale A: Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases. Cancer Epidemiol Biomarkers Prev 2: 125-129, 1993
11. Risteli J, Elomaa I, Niemi S, Novamo A,Risteli L: Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 39: 635-640, 1993
12. Catalona WJ, Scott WW: Carcinoma of the prostate. In Campbell's Urology, 5th ed, Walsh PC, Gittes RF, Perlmutter AD, Stamey TA, eds, W.B. Saunders, Philadelphia. p1463-1534, 1986
13. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, Moinuddin M: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61: 195-202, 1988
14. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143: 29-36, 1982
15. Bienkowski RS, Cowan MJ, McDonald JA, Crystal RG: Degradation of newly synthesized collagen. J Biol Chem 253: 4356-4363, 1978
16. Arai Y, Takeuchi H, Oishi K, Yoshida O: Osteocalcin: is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer? Prostate 20: 169-177, 1992
17. Garnero P, Vassy V, Bertholin A, Riou JP, Delmas PD: Markers of bone turnover in hyperthyroidism and the effects of treatment. J Clin Endocrinol Metab 78: 955-959, 1994
18. Pecherstorfer M, Zimmer-Roth I, Schilling T, Woitge HW, Schmidt H, Baumgartner G, Thiebaud D, Ludwig H, Seibel MJ: The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab 80: 97-103, 1995
19. Joerring S, Jensen LT, Andersen GR, Johansen JS: Types I and III procollagen extension peptides in serum respond to fracture in humans. Arch Orthop Trauma Surg 111: 265-267, 1992
20. Li F, Iqbal J, Wassif W, Kaddam I, Moniz C: Carboxyterminal propeptide of type I procollagen in osteomalacia. Calcif Tissue Int 55: 90-93, 1994
21. Simon LS, Krane SM, Wortman PD, Krane IM, Kovitz KL: Serum levels of type I and III procollagen fragments in Paget's disease of bone. J Clin Endocrinol Metab 58: 110-120, 1984
22. Kushida K, Takahashi M, Kawana K, Inoue T: Comparison of markers for bone formation and resorption in premenopausal and postmenopausal subjects, and osteoporosis patients. J Clin Endocrinol Metab 80: 2447-2450, 1995
23. Hakala M, Risteli L, Manelius J, Nieminen P, Risteli J: Increased type I collagen degradation correlates with disease severity in rheumatoid arthritis. Ann Rheum Dis 52: 866-869, 1993
24. Wenisch C, Bankl HC, Schonthal E, Myskiw D, Presterl E, Rumpold H, Graninger W: Serum levels of the carboxy-terminal cross-linked telopeptide of type I collagen and laminin are elevated in Graves' disease but not in toxic nodular goiter. Clin Immunol Immunopathol 75: 225-230, 1995
25. Chybowski FM, Kellr JJ, Bergstralh EJ, Oesterling JE: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 145: 313-318, 1991
26. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh PC: Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143: 747-752, 1990